Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.47 |
| ▸ | USP19 | O94966 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29010221 | 0.93 | CYP46A1 (0.54) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL1208730 | 0.93 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL4359832 | 0.91 | KDM1A (0.52) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL4392312 | 0.90 | FNTA (0.57) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL4387744 | 0.89 | F2 (0.48) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL6891931 | 0.89 | CYP46A1 (0.56) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL12523823 | 0.88 | P2RX7 (0.53) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL8386105 | 0.88 | KMT2A (0.52) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL6411056 | 0.87 | FAAH (0.53) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL3622805 | 0.87 | MEN1 (0.51) | SMN1; SMN2NPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107098886-B | Prazinone-containing quinazolinone PARP-1/2 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-07-14 | — | — | CN | disclosed |
| US-7517532-B2 | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517532-B2 | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517532-B2 | Dihydroxypyridopyrazine-1,6-dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1539714-B1 | 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1539714-B1 | 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7399763-B2 | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399763-B2 | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-07-15 | — | — | US | disclosed |
| US-7399763-B2 | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1549315-A4 | DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1539714-A4 | 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO INC (US) | 2007-04-25 | — | — | EP | disclosed |
| US-20060024330-A1 | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | disclosed |
| US-20050288293-A1 | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors | MERCK SHARP & DOHME CORP. | 2005-12-29 | — | — | US | disclosed |
| EP-1549315-A2 | DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| EP-1539714-A2 | 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004047725-A2 | 8-HYDROXY-1-OXO-TETRAHYDROPYRROLOPYRAZINE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO. INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004024078-A2 | DIHYDROXYPYRIDOPYRAZINE-1,6-DIONE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060024330-A1 | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors | DHPS, DUT, CDKN1A | SMN1; SMN2 3798/4885NPC1 4260/4885RAB9A 2836/4885 |
| US-20050288293-A1 | 8-hydroxy-1-oxo-tetrahydropyrrolopyrazine compounds useful as hiv integrase inhibitors | TYMP, TOP1, REV1 | SMN1; SMN2 3933/4885NPC1 1278/4885RAB9A 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.